[Conference presentation] Presenting the 18th Clinical Trials on Alzheimer’s Disease conference (CTAD)

Sysmex Corporation presented the latest data on the development of blood-based biomarkers for Alzheimer's Disease at 18th Clinical Trials on Alzheimer’s Disease conference (CTAD) annual meeting held from December 1^st to 4^th, 2025 in San Diego, USA.

[Poster presentation]

Session	Subject	Presenter (Affiliation)
02. CLINICAL TRIALS: RESULT P092^*1	Analytical and clinical validation of the APOE genotyping PCR test in patients from the Phase III Clarity AD trial Overview of presentation	Kozue Matsuda (SYSMEX)
07. CLINICAL TRIALS: BIOMARKERS INCLUDING PLASMA P227	Development of MTBR-tau Fragment Assay Using a Fully Automated Immunoassay System Overview of presentation	Shun Murakami (SYSMEX)
07. CLINICAL TRIALS: BIOMARKERS INCLUDING PLASMA P226^*2	Performance of plasma pTau217/Aβ42 ratio and pTau217 to predict Aβ pathology status defined by CSF testing in SPIN cohort Overview of presentation	Yuko Mori (Sysmex R&D Center Europe)

Session

Subject

Presenter
(Affiliation)

02. CLINICAL TRIALS:
RESULT
P092^*1

Analytical and clinical validation of the APOE genotyping PCR test in patients
from the Phase III Clarity AD trial

Overview of presentation

Kozue Matsuda
(SYSMEX)

07. CLINICAL TRIALS:
BIOMARKERS
INCLUDING PLASMA
P227

Development of MTBR-tau Fragment Assay Using a Fully Automated
Immunoassay System

Overview of presentation

Shun Murakami
(SYSMEX)

07. CLINICAL TRIALS:
BIOMARKERS
INCLUDING PLASMA
P226^*2

Performance of plasma pTau217/Aβ42 ratio and pTau217 to predict
Aβ pathology status defined by CSF testing in SPIN cohort

Overview of presentation

Yuko Mori
(Sysmex R&D Center Europe)

[Poster Presentation by Prof. Charlotte Teunissen, Amsterdam UMC]

Session

Subject

07. CLINICAL TRIALS:
BIOMARKERS
INCLUDING PLASMA
P197^*3

High diagnostic performance of the random-access HISCL-5000 pTau217, Aβ42 and Aβ40 plasma assays
for detecting amyloid pathology across the Alzheimer’s disease clinical continuum.

Overview of presentation

[Poster Presentation from the Tokyo Metropolitan Institute for Geriatrics and Gerontology]

Session

Subject

07. CLINICAL TRIALS:
BIOMARKERS
INCLUDING PLASMA
P228^*4

Combination of Plasma Aβ42/40 and p-tau217 Measured Using Fully Automated Immunoassay System
Accurately Predicts Amyloid Pathology Determined by Amyloid PET

Overview of presentation

All abstracts were presented at CTAD25 and published in the Journal of Prevention Alzheimer's Disease.

Terminology
*1 Co-presentation with Eisai Co., Ltd.
*2 Co-presentation with Hospital de la Santa Creu i Sant Pau, Spain
*3 Co-presentation with Amsterdam UMC
*4 Co-presentation with Tokyo Metropolitan Institute for Geriatrics and Gerontology

Information contained in the news and event is current as of the date of the announcement,
but may be subject to change without prior notice.

Back to "News / Event"